AVEO Pharmaceuticals Inc

NASDAQ:AVEO   3:59:54 PM EDT
6.69
+0.13 (+1.98%)
Products, Strategic Combinations, Regulatory

Aveo Oncology Announces Clinical Trial Collaboration And Supply Agreement With Eli Lilly And Co

Published: 06/22/2022 13:26 GMT
AVEO Pharmaceuticals Inc (AVEO) - Aveo Oncology Announces Clinical Trial Collaboration and Supply Agreement With Eli Lilly and Company for Erbitux® (cetuximab) in North America to Evaluate Ficlatuzumab and Cetuximab in Patients With Recurrent Or Metastatic Hnscc.
Aveo Oncology - Potential Phase 3 Registrational Clinical Trial in Hpv Negative R/m Hnscc Expected in 1h 2023.
Aveo Oncology - Under Agreement, Lilly Will Provide Cetuximab Clinical Drug Supply in U.S. and Canada for Aveo's Potential Registrational Study.
Aveo Oncology - Aveo Will Serve As Study Sponsor and Will Be Responsible for Trial Execution.
Aveo Oncology - Expects to Continue to Discuss Potential Ficlatuzumab Pivotal Study Designs With FDA and to Continue Ongoing Partnership Dialogues.